Watanabe, Hirotoshi
Morimoto, Takeshi
Ogita, Manabu
Suwa, Satoru
Natsuaki, Masahiro
Suematsu, Nobuhiro
Koeda, Yorihiko
Morino, Yoshihiro
Nikaido, Akira
Hata, Yoshiki
Doi, Masayuki
Hibi, Kiyoshi
Kimura, Kazuo
Yoda, Shunsuke
Kaneko, Takeo
Nishida, Koji
Kawai, Kazuya
Yamaguchi, Koji
Wakatsuki, Tetsuzo
Tonoike, Norimasa
Yamamoto, Masashi
Shimizu, Shogo
Shimohama, Takao
Ako, Junya
Kimura, Takeshi
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
https://doi.org/10.1161/circinterventions.122.012004
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial
https://doi.org/10.1161/circinterventions.120.010384
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
https://doi.org/10.1007/s12928-020-00719-6
Funding for this research was provided by:
Abbott Japan
Article History
Received: 27 August 2020
Accepted: 7 October 2020
First Online: 12 November 2020
Change Date: 25 November 2020
Change Type: Update
Change Details: The missed supplementary material has been included
Change Date: 12 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12928-020-00741-8
Compliance with ethical standards
:
: STOPDAPT-2 is funded by Abbott Vascular Japan. Junya Ako receives lecture fees from Abbott Vascular Japan, Sanofi, Daiichi-Sankyo, and AstraZeneca. Takeshi Kimura serves as an advisory role to Abbott Vascular Japan and received a research grant from Daiichi-Sankyo. Others have no conflict of interests.
: The STOPDAPT-2 was approved by Kyoto University Certified Review Board (Reference number; YC1114). The STOPDAPT-2 genotype substudy was approved by Kyoto University Graduate School of Medicine, Ethics Committee (Reference number; G0781).